TY - JOUR
T1 - Evaluation of Antibody Response and Adverse Effects following Heterologous COVID-19 Vaccine Booster with mRNA Vaccine among Healthcare Workers in Indonesia
AU - Soegiarto, Gatot
AU - Mahdi, Bagus Aulia
AU - Wulandari, Laksmi
AU - Fahmita, Karin Dhia
AU - Hadmoko, Satrio Tri
AU - Gautama, Hendra Ikhwan
AU - Prasetyaningtyas, Dewi
AU - Prasetyo, Muhammad Edwin
AU - Negoro, Pujo Prawiro
AU - Arafah, Nur
AU - Purnomosari, Dewajani
AU - Tinduh, Damayanti
AU - Husada, Dominicus
AU - Baskoro, Ari
AU - Fetarayani, Deasy
AU - Nurani, Wita Kartika
AU - Oceandy, Delvac
N1 - Funding Information:
This research was funded by Universitas Airlangga Mandate Research Grant, grant number 1043/UN3.15/PT/2021. The APC was funded by Universitas Airlangga.
Publisher Copyright:
© 2023 by the authors.
PY - 2023/7
Y1 - 2023/7
N2 - Background: The administration of the third (or booster) dose of COVID-19 vaccine is important in maintaining protection against SARS-CoV-2 infection or the severity of the disease. In Indonesia, health care workers (HCWs) are among the first to receive a booster dose of the COVID-19 vaccine. In this study, we evaluated the antibody response and adverse events following heterologous booster vaccine using mRNA-1273 among HCWs that were fully vaccinated with inactivated viral vaccine as the priming doses. Methods: 75 HCWs at Dr. Soetomo General Hospital in Surabaya, Indonesia, participated in this study. The level of antibody against the SARS-CoV-2 receptor binding domain was analyzed at 1, 3, and 5 months following the second priming dose and at 1, 3, and 5 months after the booster dose. Results: We found a significantly higher level of antibody response in subjects receiving a booster dose of the mRNA-1273 vaccine compared to those receiving an inactivated viral vaccine as a booster. Interestingly, participants with hypertension and a history of diabetes mellitus showed a lower antibody response following the booster dose. There was a higher frequency of adverse events following injection with the mRNA-1273 vaccine compared to the inactivated viral vaccine, although the overall adverse events were considered minor. Conclusions: A heterologous booster dose using mRNA vaccine resulted in a high antibody response; however, participants with hypertension and diabetes mellitus displayed a lower antibody response.
AB - Background: The administration of the third (or booster) dose of COVID-19 vaccine is important in maintaining protection against SARS-CoV-2 infection or the severity of the disease. In Indonesia, health care workers (HCWs) are among the first to receive a booster dose of the COVID-19 vaccine. In this study, we evaluated the antibody response and adverse events following heterologous booster vaccine using mRNA-1273 among HCWs that were fully vaccinated with inactivated viral vaccine as the priming doses. Methods: 75 HCWs at Dr. Soetomo General Hospital in Surabaya, Indonesia, participated in this study. The level of antibody against the SARS-CoV-2 receptor binding domain was analyzed at 1, 3, and 5 months following the second priming dose and at 1, 3, and 5 months after the booster dose. Results: We found a significantly higher level of antibody response in subjects receiving a booster dose of the mRNA-1273 vaccine compared to those receiving an inactivated viral vaccine as a booster. Interestingly, participants with hypertension and a history of diabetes mellitus showed a lower antibody response following the booster dose. There was a higher frequency of adverse events following injection with the mRNA-1273 vaccine compared to the inactivated viral vaccine, although the overall adverse events were considered minor. Conclusions: A heterologous booster dose using mRNA vaccine resulted in a high antibody response; however, participants with hypertension and diabetes mellitus displayed a lower antibody response.
KW - COVID-19
KW - adverse event
KW - antibody response
KW - booster
KW - comorbidity
KW - healthcare worker
KW - inactivated viral vaccine
KW - mRNA vaccine
KW - vaccine
UR - http://www.scopus.com/inward/record.url?scp=85166397345&partnerID=8YFLogxK
U2 - 10.3390/vaccines11071160
DO - 10.3390/vaccines11071160
M3 - Article
AN - SCOPUS:85166397345
SN - 2076-393X
VL - 11
JO - Vaccines
JF - Vaccines
IS - 7
M1 - 1160
ER -